Overall recurrence rate was 9.7 % (n = 10) in ypN0 patients; recurrences occurred in two patients with HR+/HER2+, four patients with HR-/HER2+ and four patients with TN breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.